NEW YORK (GenomeWeb News) – Illumina said today that its noninvasive prenatal testing subsidiary Verinata Health has signed an exclusive agreement with Teva Pharmaceutical Industries to commercialize its Verifi test in Israel.
Under the terms of the five-year agreement, Teva will be the exclusive distributor of Verifi in Israel. All tests will be run in Verinata's CLIA-certified laboratory in California, while Israel's Clalit Health Services will provide reimbursement for Verifi through supplemental insurance.
The MOR Institute of Medical Data, through its relationship with Teva, will make the test available to customers of Clalit Health Services who are at a high risk of having a fetus with a chromosomal abnormality. Additionally, Clalit Health Services will establish a 9,000-patient clinical outcomes registry to collect performance data that it will share with Verinata.
Beginning today, MOR will provide a nursing service that allows women to have their sample collected from their homes as well as from MOR clinics.
"With the test now available in several international markets, we look forward to expanding our commercial presence by continuing to partner with leading organizations around the globe," Verinata's VP of global commercial operations, Vance Vanier, said in a statement.